Profile data is unavailable for this security.
About the company
Pila Pharma AB is a Sweden-based clinical stage pharmaceutical company, active in the biotechnology sector. The Company conducts clinical tests in phase 2 with drugs against type 2 diabetes. The target product is a tablet that is taken orally in an early stage of diabetes to restore the body's insulin production and thereby reduce the patient's blood sugar level. PILA PHARMA's patent-protected product candidate is called XEN-D0501 and is a TRPV1 antagonist, a novel type of oral anti-diabetic agent for treatment of type 2 diabetes. Pila Pharma AB has completed two phase 2a clinical trials (PP-CT01 and PP-CT02), that both demonstrated that XEN-D0501 is well tolerated by people with type 2 diabetes. In addition, the product is expected to have fewer unwanted side effects than alternative forms of treatment.
- Revenue in SEK (TTM)1.46m
- Net income in SEK-9.93m
- Incorporated2014
- Employees1.00
- LocationPila Pharma ABVastergatan 1MALMO 211 21SwedenSWE
- Websitehttps://pilapharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Immunovia AB (publ) | 1.21m | -260.73m | 64.76m | 11.00 | -- | 1.48 | -- | 53.43 | -6.06 | -6.06 | 0.0276 | 0.9648 | 0.0075 | 58.23 | 14.96 | 110,181.80 | -160.93 | -41.33 | -194.89 | -44.24 | -5,523.76 | -7,553.76 | -21,512.13 | -20,879.29 | 2.03 | -- | 0.1675 | -- | 37.55 | 36.48 | -84.09 | -- | -50.93 | -- |
| ExpreS2ion Biotech Holding AB | 7.77m | -77.95m | 65.80m | 18.00 | -- | 1.26 | -- | 8.47 | -1.56 | -1.56 | 0.1509 | 1.02 | 0.0821 | -- | 4.87 | 298,730.80 | -82.36 | -63.54 | -113.92 | -75.88 | -132.91 | -1.94 | -1,003.55 | -524.31 | -- | -- | 0.0055 | -- | 43.07 | -0.1561 | 22.94 | -- | 19.90 | -- |
| Spago Nanomedical AB (publ) | 1.47m | -35.58m | 65.84m | 12.00 | -- | 1.92 | -- | 44.91 | -0.3129 | -0.3129 | 0.0113 | 0.1525 | 0.0324 | -- | 9.91 | 112,769.20 | -78.60 | -20.19 | -93.27 | -20.97 | -5.25 | -- | -2,426.88 | -4,853.45 | -- | -- | 0.00 | -- | 14.14 | -- | -7.72 | -- | -- | -- |
| Klaria Pharma Holding AB (publ) | -6.53m | -20.10m | 67.73m | 5.00 | -- | 1.90 | -- | -- | -0.1847 | -0.4021 | -0.0621 | 0.2743 | -0.0794 | -- | -- | -1,305,600.00 | -24.44 | -37.28 | -40.23 | -51.56 | -- | -- | -- | -2,077.34 | -- | -1.87 | 0.00 | -- | -100.00 | -- | 71.17 | -- | -- | -- |
| Combigene AB | 3.70m | -35.24m | 69.11m | 8.00 | -- | 0.6758 | -- | 18.67 | -1.78 | -1.78 | 0.187 | 5.16 | 0.0294 | -- | 1.27 | 462,765.00 | -27.99 | -13.00 | -29.40 | -14.58 | -- | -- | -951.98 | -58.77 | -- | -- | 0.00 | -- | -79.23 | 268.58 | -479.27 | -- | -24.02 | -- |
| Abera Bioscience AB | 0.00 | -12.70m | 70.16m | 6.00 | -- | 7.13 | -- | -- | -0.9261 | -0.9261 | 0.00 | 0.6407 | 0.00 | -- | -- | 0.00 | -90.08 | -79.42 | -117.23 | -96.10 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 13.74 | -- | -- | -- |
| PCI Biotech Holding ASA | 3.00m | -20.38m | 72.33m | 7.00 | -- | 1.85 | -- | 24.12 | -0.5443 | -0.5443 | 0.0801 | 1.05 | 0.0556 | -- | 0.6848 | 427,142.80 | -37.78 | -36.44 | -41.97 | -40.14 | -- | -- | -679.43 | -1,055.43 | -- | -- | 0.0081 | -- | -37.05 | -20.78 | 63.13 | -- | -- | -- |
| Prolight Diagnostics AB (publ) | 0.00 | -136.81m | 72.47m | 16.00 | -- | 0.5829 | -- | -- | -0.3953 | -0.3953 | 0.00 | 0.2488 | 0.00 | -- | -- | 0.00 | -64.42 | -- | -84.94 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -13.84 | -- |
| Pila Pharma AB | 1.46m | -9.93m | 73.76m | 1.00 | -- | 11.07 | -- | 50.42 | -0.5304 | -0.5304 | 0.0767 | 0.28 | 0.1513 | -- | 6.11 | 1,463,020.00 | -102.68 | -108.88 | -122.66 | -121.45 | -127.88 | -42.67 | -678.73 | -1,577.64 | -- | -159.47 | 0.104 | -- | -22.21 | -- | 62.92 | -- | -- | -- |
| Chosa Oncology AB | 73.00k | -23.94m | 73.78m | -- | -- | 3.88 | -- | 1,010.71 | -1.11 | -1.11 | 0.0018 | 0.2684 | 0.003 | -- | 0.013 | -- | -96.68 | -51.96 | -178.66 | -61.92 | -- | -- | -32,798.63 | -708.47 | -- | -97.97 | 0.00 | -- | -98.21 | -- | 28.33 | -- | -- | -- |
| ViroGates A/S | 8.78m | -19.52m | 77.01m | 10.00 | -- | 3.75 | -- | 8.77 | -6.00 | -6.00 | 1.44 | 2.08 | 0.3344 | 0.316 | 3.64 | 573,300.00 | -74.36 | -46.58 | -80.05 | -52.09 | 77.20 | 77.91 | -222.40 | -238.01 | 10.45 | -19.08 | 0.2833 | -- | -45.01 | 10.98 | -25.40 | -- | -- | -- |
| Dextech Medical AB | 0.00 | -4.53m | 78.01m | 1.00 | -- | 2.52 | -- | -- | -0.2449 | -0.2449 | 0.00 | 1.67 | -- | -- | -- | -- | -- | -28.96 | -- | -29.94 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 12.89 | -- | 0.412 | -- |
| Peptonic Medical AB | 39.05m | -45.25m | 81.38m | 37.00 | -- | 0.3277 | -- | 2.08 | -0.025 | -0.025 | 0.0222 | 0.0323 | 0.4185 | 1.42 | 5.49 | 1,055,432.00 | -48.49 | -46.02 | -61.53 | -60.85 | 44.34 | 54.26 | -115.88 | -139.38 | 0.5002 | -140.41 | 0.2084 | -- | -14.93 | 149.65 | -15.55 | -- | 27.15 | -- |
| Ziccum AB | 6.64m | -20.50m | 87.62m | 9.00 | -- | 6.68 | -- | 13.21 | -1.46 | -1.46 | 0.4721 | 0.8534 | 0.2696 | -- | 22.01 | 829,375.00 | -83.29 | -68.51 | -106.42 | -76.47 | -- | -- | -308.94 | -2,598.03 | -- | -- | 0.0516 | -- | -- | 75.20 | 25.62 | -- | -13.45 | -- |
| Sprint Bioscience AB | 68.36m | 8.77m | 89.93m | 36.00 | 10.26 | 3.64 | 9.64 | 1.32 | 0.1256 | 0.1256 | 0.9791 | 0.3538 | 1.58 | -- | 11.45 | 2,441,286.00 | 20.29 | -71.22 | 43.20 | -113.71 | 80.06 | 62.75 | 12.83 | -110.22 | -- | -- | 0.00 | -- | 60,725.30 | 22.99 | 99.27 | -- | -26.02 | -- |
| Biosergen AB | 0.00 | -27.04m | 90.76m | 4.00 | -- | 13.25 | -- | -- | -0.3475 | -0.3475 | 0.00 | 0.0247 | 0.00 | -- | -- | 0.00 | -131.31 | -- | -217.09 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 32.25 | -- | -- | -- |
Data as of Jun 03 2024. Currency figures normalised to Pila Pharma AB's reporting currency: Swedish Krona SEK
